Sanofi India Limited has announced an upcoming analyst and institutional investor meeting scheduled for April 1, 2026, in Mumbai. The pharmaceutical company made this disclosure on March 24, 2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically under Regulation 30 read with Schedule III.

Meeting Details

The company has provided specific details regarding the upcoming investor engagement session:

Regulatory Compliance and Information Disclosure

Sanofi India Limited has emphasized its commitment to regulatory compliance and transparent communication practices. The company has clearly stated that all discussions during the meetings will be strictly limited to information already available in the public domain. This approach ensures adherence to SEBI guidelines regarding the disclosure of material information.

The pharmaceutical company has specifically assured that no Unpublished Price Sensitive Information (UPSI) will be disclosed during these investor interactions. This commitment aligns with regulatory requirements designed to maintain market integrity and ensure fair access to material information.

Flexibility and Accessibility

The company has noted that the meeting schedule remains subject to change due to potential exigencies on the part of either the investors or the company. This flexibility allows for adjustments based on unforeseen circumstances while maintaining the commitment to stakeholder engagement.

Additionally, Sanofi India Limited has indicated that information regarding the analyst and investor meet will be made available on the company's official website, ensuring broader accessibility for interested stakeholders who may not be able to attend the in-person sessions.

The announcement was signed by Haresh Vala, Company Secretary and Compliance Officer, demonstrating the company's formal approach to regulatory communications and stakeholder engagement.

Sanofi India Limited has issued a public notice regarding the mandatory transfer of equity shares to the Investor Education and Protection Fund (IEPF) Authority for shareholders who have not claimed their dividends for seven consecutive years or more.

Regulatory Compliance Notice

The company has published newspaper advertisements on March 14, 2026, in Business Standard (English) and Sakal (Marathi) newspapers, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This notice addresses shareholders whose shares are liable for transfer to the IEPF as per Section 124(6) of the Companies Act, 2013.

Transfer Requirements and Timeline

Under the Companies Act, 2013 and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, companies must transfer all shares to the IEPF demat account where dividends have remained unclaimed for seven consecutive years or more.

Sanofi India has sent separate communications dated March 13, 2026, to all affected shareholders who have not encashed their final dividend for financial year 2018 and subsequent dividends declared by the company.

Shareholder Action Required

Shareholders are requested to forward requisite documents to either the company or its Registrar and Transfer Agent, MUGF Intime India Private Limited (formerly Link Intime India Private Limited), to claim unclaimed dividend amounts and shares. A comprehensive list of shareholders who have not encashed dividends for seven consecutive years is available on the company's website.

Recovery Process for Transferred Shares

Once shares are transferred to IEPF, all future benefits will be issued in favor of the IEPF Authority. However, shareholders can reclaim both unclaimed dividends and transferred shares by:

• Making an online application in prescribed e-form IEPF-5
• Obtaining an entitlement letter from the company
• Submitting required documents as enumerated in the e-form
• Following the procedure outlined on the IEPF website at www.iepf.gov.in

Contact Information

For queries related to this matter, shareholders can contact:

The notice emphasizes that no claims will be entertained against the company once shares are transferred to IEPF, making it crucial for eligible shareholders to act before the June 13, 2026 deadline.